Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Phase 3 × beta-Thalassemia × luspatercept × Clear all

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Conditions

beta-Thalassemia 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Anemia 2 Primary Myelofibrosis 1 Higher-risk Myelodysplastic Syndrome 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04064060 2025-11-12

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT02604433 2023-04-18

BELIEVE

Celgene

Phase 3 Completed

336 enrolled 38 charts 1 FDA

beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡